Clinical Trial Update: A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition [Phase 4]

View source ↗

Summary

Phase 4 study evaluating oxybutynin for neurogenic detrusor overactivity has completed, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity

Drugs mentioned

• oxybutynin (oxybutynin)

Snippet

Sponsor: Watson Pharmaceuticals | Conditions: Detrusor Hyperreflexia | Phase 4 | Status: COMPLETED | Results posted: 2010-04-30